Treatment News : Shingles Still More Common in People With HIV - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 10, 2012

Shingles Still More Common in People With HIV

by Tim Horn

New cases of herpes zoster, better known as shingles, appear to be on the decline among people living with HIV, but rates are still higher than those seen in the general population, according to Johns Hopkins University School of Medicine data published online ahead of print by the Journal of Acquired Immune Deficiency Syndromes.

The researchers, under the direction of Leah Blank, MD, MPH, also noted that more than one-quarter of all new shingles cases in their HIV cohort were complicated, a “remarkable” finding in light of the young age of the patient population.

Shingles is caused by the varicella zoster virus (VZV), best known for its ability to cause chickenpox (varicella) in children. VZV isn’t cleared from the body after a bout of chickenpox, but rather remains dormant in nerve clusters near the spine. If cellular immunity to VZV dwindles—which can happen in people living with HIV, advancing in age or undergoing treatment that depletes immune function—VZV can become reactivated, leading to a shingles outbreak.

Shingles typically causes a rash-like string of blisters that follow the path of a nerve extending from the spinal cord (known as a dermatomal pattern). While often painful, shingles is usually benign; it can last three to four weeks without causing otherwise serious or long-term problems. Sometimes, however, the disease can be complicated by recurrences, internal organ damage and multiple dermatomal patterns.

Shingles has long been more common among people living with HIV, particularly among young people infected with the virus compared with age-matched individuals in the general population. In the years following the widespread availability of combination antiretroviral therapy, studies didn’t show that the risk of shingles was decreasing. In fact, some researchers suggested that the incidence may increase, given that people are now living with HIV longer and because shingles may be an adverse effect of the immune reconstitution syndrome that can occur in people with low CD4 cell counts responding otherwise favorably to antiretroviral treatment.

To get a sense of the modern-day incidence of shingles, including complicated cases, Blank and her colleagues identified herpes zoster episodes documented between 2002 and 2009 at Johns Hopkins. For each case the researchers identified, three HIV-negative controls were included in the analysis so that potential shingles outbreak risk factors could be assessed.

Researchers identified 183 new (incident) shingles cases among the more than 4,300 HIV-positive patients; an additional 138 patients were also diagnosed with shingles, but these were recurrent episodes.

The incidence rate during the entire study period was 9.3 new shingle cases per 1,000 person-years of follow-up. While the study did not show a statistically significant trend in the incidence of shingles over time, the authors note that the incidence rate was significantly lower than the one documented in a previous study of the same cohort. Between 1997 and 2001, Blank and her colleagues explain, the incidence rate during the study period was 32 new shingle cases per 1,000 person-years of follow-up.

The authors add that the apparent reduced incidence in the Johns Hopkins study conflicts with results from two other cohorts—the Veterans Health database (2000–2007) and Olmsted County, Minnesota, surveillance data (1996–2001)—that both showed small, but statistically significant, increases in shingles over time.

“The observed decrease in incidence rate in our clinic might be explained by improvements in addressing the risk factors for herpes zoster specific to [people living with HIV],” the authors explain. “Consistent with our earlier study and other studies, we found that a lower CD4 count was associated with increased risk of incident herpes zoster. Indeed, immune suppression is consistently a risk factor for herpes zoster outbreak in this population, with a CD4 count below 350 [conferring] greater risk than a CD4 count between 350 and 500. Given the median CD4 count of our population has steadily increased from 2009 from 298 to 431 cells, this finding highlights the importance of restoring immune function in protecting against herpes zoster.”

Blank and her colleagues stress, however, that the incidence rate is still greater than the general population, especially when age is considered.

Also of concern was the high rate of complicated herpes zoster—28 percent of those with shingles experienced disseminated shingles (three or more dermatomal patterns), disease of the eye or internal organs, neurological complications or recurrence within six months. While this rate of complicated shingles in people living with HIV is consistent with other cohorts, Blank and her fellow authors note the 28 percent rate is lower than the one documented in the earlier Johns Hopkins cohort: 53 percent.

In addition to low CD4 cell counts and detectable viral loads being associated with shingles outbreaks, Blank’s team determined that outbreaks were more likely to occur within 90 days of starting antiretroviral therapy, confirming that shingles is a possible complication of the immune reconstitution syndrome that can occur in people beginning HIV therapy with low CD4 cells. “Herpes zoster does appear to be associated with immune reconstitution, so the clinician should be aware of the higher risk of herpes zoster shortly after antiretroviral therapy is started,” they write.

Herpes zoster vaccination—or the lack thereof in the cohort—also appears to be a risk factor. “Despite the high complication rate, and the high incidence rate in [people living with HIV], not a single patient in our study population had been vaccinated against herpes zoster,” Blank and her colleagues wrote.

Search: herpes zoster, shingles, varicella, hiv, johns hopkins, incidence, postherpetic neuralgia

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 7 (of 7 total)    

charles albertson, jax, 2014-10-17 13:58:24
I am a 60 year old man and have been hiv pos since 1986.I have been dealing with mild shingles for most of that time. No matter what my dcd4 is,now at 600,they come out. Untill now it was just a small irritation,a couple blisters several times a year. Noww it is a full scale string about a foot long coming from my spine. A very different sition than usual.

mmplus, , 2012-11-29 07:01:11
I have shingles on my face now (Nov2012), first time and taking acyclovir. My cd4 last Sep2012 was at 249. I just read above that the risk is high with cd4 below 350. If this is true, i need to wait for few months to achieve that level.... praying.

Gene, Corona, 2012-07-12 14:24:41
I had an outbreak of shingles approx. 6 years ago. I was diagnosed with full AIDS two years later. Would the Shingles vaccination be to my advantage now. Should I get vaccinated+

Thom, USA, 2012-07-11 22:40:09
The simple truth is that we just do not know when it comes to medical facts, there really are none, we think we understand how everything works but you know every few years we learn about things we thought we used to know were true but now we find they were false based on flawed information.

Just as in the past medical doctors used to think that shock treatment was a good thing that it really worked, we now know it was evil but back in the 1950s they "Thought" they knew it all, this is that.

MARY SOILEX, LOS ANGELES, CA, 2012-07-11 18:59:02
I GOT DAS SHINGLES UND I GOT AN ITCH!! It aint fun und i do sympathize with all who have endured this condition. GET the vaccine I say... WATT ABOUT DAS VACCINE???

Dave, Canada, 2012-07-11 12:41:16
I would like to know if HIV+ individuals SHOULD receive the vaccine, that is, is it EFFICACIOUS for us? The fine print on the vaccine ad says HIV+ people should NOT take it. Need a good answer. I would think the immune system could use a kick start to fight the virus if it ever made a comeback after so many years since childhood. What are the pros and cons, esp. for undetectable persons with reasonable CD4's?

Noel, Portland, 2012-07-11 11:52:50
In the State of Oregon pharmacists will not administer the Shingles vaccine to HIV+ people. Even if your CD4 count is in the normal range. Makes me angry!

comments 1 - 7 (of 7 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.